FDA 召回执法报告 D-0728-2026：Fresenius Kabi USA 的 Xylocaine 注射液因发现毛发类颗粒物被列为 II 级召回
FDA drug enforcement D-0728-2026: Fresenius Kabi USA, LLC — Presence of Particulate Matter: Hair was found in products
FDA 在药品召回执法报告 D-0728-2026 中将 Fresenius Kabi USA 的 Xylocaine（利多卡因盐酸盐注射液，USP）1%、每 20 mL 200 mg 的多剂量瓶列为 II 级召回，原因是产品中发现毛发类颗粒物。
该条为 FDA 已分级召回记录，列出 Xylocaine 注射液的批次、数量与分销范围，可用于核对该记录的产品与批次信息。
FDA 药品召回执法报告 — D-0728-2026
报告发布日期：2026-07-29。这是执法报告日期，不是召回启动日期。
范围：一条已分类的药品召回记录；event_id 可能归组多个产品。没有召回编号的未分类记录不在本数据流范围内。本记录不是新闻稿，也不是新的执法认定。
openFDA 数据集每周更新。报告状态不是实时召回状态，不得用于跟踪召回生命周期。下文其他日期保留其各自名称所对应的含义。
完整官方产品记录（包括 openFDA 统一标识符）：
{
"address_1": "3 Corporate Dr",
"address_2": "N/A",
"center_classification_date": "20260723",
"city": "Lake Zurich",
"classification": "Class II",
"code_info": "Lot #: 6130235, Exp. Date 02/2027",
"country": "United States",
"distribution_pattern": "Nationwide within in the USA",
"event_id": "99449",
"initial_firm_notification": "Letter",
"openfda": {
"application_number": [
"NDA006488"
],
"brand_name": [
"XYLOCAINE"
],
"generic_name": [
"LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE"
],
"is_original_packager": [
true
],
"manufacturer_name": [
"Fresenius Kabi USA, LLC"
],
"package_ndc": [
"63323-492-04",
"63323-492-27",
"63323-492-09",
"63323-492-57",
"63323-492-07",
"63323-492-37",
"63323-492-03",
"63323-492-31",
"63323-491-01",
"63323-491-57",
"63323-495-09",
"63323-495-27",
"63323-495-04",
"63323-495-07",
"63323-485-01",
"63323-485-27",
"63323-485-03",
"63323-485-57",
"63323-486-01",
"63323-486-17",
"63323-486-02",
"63323-486-27",
"63323-486-05",
"63323-486-57",
"63323-484-57",
"63323-489-02",
"63323-489-27",
"63323-489-03",
"63323-489-21",
"63323-489-01",
"63323-489-17",
"63323-488-07",
"63323-488-37",
"63323-488-03",
"63323-488-31",
"63323-488-01",
"63323-488-17",
"63323-481-01",
"63323-481-57",
"63323-483-03",
"63323-483-27",
"63323-483-01",
"63323-483-57",
"63323-482-01",
"63323-482-17",
"63323-482-03",
"63323-482-27",
"63323-482-05",
"63323-482-57",
"63323-487-01",
"63323-487-17",
"63323-487-07",
"63323-487-37",
"63323-487-03",
"63323-487-31"
],
"product_ndc": [
"63323-481",
"63323-492",
"63323-491",
"63323-495",
"63323-485",
"63323-486",
"63323-484",
"63323-489",
"63323-488",
"63323-483",
"63323-482",
"63323-487"
],
"product_type": [
"HUMAN PRESCRIPTION DRUG"
],
"route": [
"INFILTRATION",
"PERINEURAL"
],
"rxcui": [
"1010033",
"1010035",
"1010671",
"1010673",
"1010688",
"1010692",
"1010745",
"1010749",
"1010751",
"1010755",
"1010759",
"1010763",
"1010900",
"1010902",
"1737343",
"1737345",
"1737562",
"1737563",
"1737566",
"1737567",
"1737568",
"1737569",
"1737570",
"1737571",
"1737757",
"1737758",
"1737761",
"1737762",
"1867938",
"1867940",
"1867943",
"1867944",
"1867992",
"1867993",
"1867996",
"1867997",
"1868028",
"1868029"
],
"spl_id": [
"ea480a68-5927-4278-9deb-2956961da428"
],
"spl_set_id": [
"ba082c2f-64f4-419d-9c88-74f203316e17"
],
"substance_name": [
"LIDOCAINE HYDROCHLORIDE ANHYDROUS",
"EPINEPHRINE BITARTRATE"
],
"unii": [
"30Q7KI53AK",
"EC2CNF7XFP"
],
"upc": [
"0363323484576",
"0363323485016",
"0363323483036",
"0363323487072",
"0363323486013",
"0363323495091",
"0363323488079",
"0363323489021",
"0363323495046",
"0363323491017",
"0363323492045",
"0363323492090",
"0363323482015",
"0363323481018"
]
},
"postal_code": "60047-8930",
"product_description": "Xylocaine (lidocaine HCl Injection, USP), 1%, 200 mg per 20 mL (10 mg per mL), 25 Multiple-Dose Vials, 20 mL, Rx only, Sterile, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-485-27; NDC Vial: 63323-485-01",
"product_quantity": "93,250 vials",
"product_type": "Drugs",
"reason_for_recall": "Presence of Particulate Matter: Hair was found in products",
"recall_initiation_date": "20260716",
"recall_number": "D-0728-2026",
"recalling_firm": "Fresenius Kabi USA, LLC",
"report_date": "20260729",
"state": "IL",
"status": "Ongoing",
"voluntary_mandated": "Voluntary: Firm initiated"
}
来源：openFDA 已分级药品召回执法报告 · api.fda.gov